Real-world results with IgPro20 for hypo- or agammaglobulinemia in Japan.
Kohsuke ImaiTomonori IshiiShigeaki NonoyamaTakahiro YasumiHirokazu KaneganeTaku FukushimaMasayuki MatsumaruTetsushi AkasakiHideo UsuiPublished in: Pediatrics international : official journal of the Japan Pediatric Society (2022)
In Japan, IgPro20 was considered safe and effective among patients with agammaglobulinemia or hypogammaglobulinemia due to PID or SID.
Keyphrases